Premium
Development of cellular and humoral response against WT 1 protein vaccination in mice
Author(s) -
Nicoli Paolo,
Calabrese Chiara,
Pellegrino Rosa Maria,
Rosso Valentina,
Bracco Enrico,
Signorino Elisabetta,
Carturan Sonia,
Petiti Jessica,
Gallo Daniela,
Gaidano Valentina,
De Gobbi Marco,
Roetto Antonella,
Saglio Giuseppe,
Cilloni Daniela
Publication year - 2015
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.24092
Subject(s) - vaccination , biology , immunology , antigen , cancer research , wilms' tumor , leukemia , immune system , epitope , peptide vaccine , genetics
To the Editor: Many anti‐cancer vaccination strategies have been tested in mice and humans in the attempt to eradicate leukemia cells 1. The vast majority of clinical trials are based on peptide vaccination which allows the induction of cellular response to specific tumor associated antigens 2. WT1(Wilms tumor‐1) gene is located on chromosome 11p13 and encodes a zinc finger transcription factor that plays an important role in cell growth and differentiation. WT1 was originally described as a tumor suppressor gene although many evidences demonstrated that it plays an oncogenic function in the setting of leukemia. WT1 protein represents an optimal tumor antigen since it is highly expressed in acute leukemias, myelodysplastic syndromes (MDS) and myeloproliferative neoplasms 3. By contrast, it is expressed at very low levels in normal hematopoietic progenitors. Expression of the WT1 protein is restricted to a limited set of tissues, including the gonads, uterus, kidney, and spleen.